Clinical Trials Using Toll-like Receptor 9 Agonist IMO-2125
Clinical trials are research studies that involve people. The clinical trials on this list are studying Toll-like Receptor 9 Agonist IMO-2125. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
Location: 9 locations
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
A Phase 2 study intended to see efficacy of tilsotolimod in combination with immunotheraphy drugs ipilimumab and nivolumab in different solid tumors.
Location: M D Anderson Cancer Center, Houston, Texas